Will Uber Stock Recover?
Shares of Uber Technologies (NYSE:UBER) have had a rough few…
Sell
24
CYTH Quote, Financials, Valuation and Earnings
Last price:
$0.63
Seasonality move
:
31.67%
Day range:
$0.62 - $0.71
52-week range:
$0.55 - $2.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.33x
P/B ratio:
68.02x
Volume:
35.8K
Avg. volume:
48K
1-year change:
-56.74%
Market cap:
$17.9M
Revenue:
$1.1M
EPS (TTM):
-$0.90
Analysts' Opinion
-
Consensus RatingCyclo Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.20, Cyclo Therapeutics has an estimated upside of 52.49% from its current price of $0.62.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.60 representing 100% downside risk from its current price of $0.62.
Fair Value
-
According to the consensus of 1 analyst, Cyclo Therapeutics has 52.49% upside to fair value with a price target of $3.20 per share.
CYTH vs. S&P 500
-
Over the past 5 trading days, Cyclo Therapeutics has overperformed the S&P 500 by 5.89% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Cyclo Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cyclo Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cyclo Therapeutics reported revenues of $233.8K.
Earnings Growth
-
Cyclo Therapeutics earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Cyclo Therapeutics reported earnings per share of -$0.31.
Enterprise value:
29.2M
EV / Invested capital:
--
Price / LTM sales:
19.33x
EV / EBIT:
--
EV / Revenue:
33.50x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.30x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$813.2K
Return On Assets:
-344.63%
Net Income Margin (TTM):
-2848.16%
Return On Equity:
-4056.09%
Return On Invested Capital:
-20419.22%
Operating Margin:
-3545.95%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $1.8M | $951.8K | $870.7K | $495.5K | $233.8K | |
| Gross Profit | $1.6M | $867.2K | $813.2K | $456.7K | $217K | |
| Operating Income | -$13.4M | -$19.4M | -$24.7M | -$4.8M | -$8.3M | |
| EBITDA | -$13.4M | -$19.4M | -$24.7M | -$4.8M | -$8.3M | |
| Diluted EPS | -$1.58 | -$1.67 | -$0.90 | -$0.29 | -$0.31 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4M | $11M | $8.4M | $5.5M | $3.3M | |
| Total Assets | $4.1M | $11.1M | $8.5M | $5.6M | $5.3M | |
| Current Liabilities | $4.6M | $3.4M | $2.9M | $6.6M | $18.7M | |
| Total Liabilities | $4.7M | $3.5M | $2.9M | $6.6M | $18.7M | |
| Total Equity | -$524.5K | $7.6M | $5.6M | -$1.1M | -$13.5M | |
| Total Debt | $158.5K | $151.7K | -- | -- | $12.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15M | -$14.6M | -$22.5M | -$4M | -$8.2M | |
| Cash From Investing | $48.5K | -- | -- | -- | -- | |
| Cash From Financing | $10.8M | $12.1M | $21.6M | $5M | $8M | |
| Free Cash Flow | -$15M | -$14.6M | -$22.5M | -$4M | -$8.2M | |
CYTH
Sector
Market Cap
$17.9M
$47.5M
Price % of 52-Week High
29.46%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
-12.98%
-0.74%
1-Year Price Total Return
-56.74%
-34.04%
Beta (5-Year)
-0.485
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.63
200-day SMA
Sell
Level
$1.00
Bollinger Bands (100)
Sell
Level
0.6 - 0.82
Chaikin Money Flow
Sell
Level
-50.8M
20-day SMA
Sell
Level
$0.62
Relative Strength Index (RSI14)
Sell
Level
47.99
ADX Line
Buy
Level
14.68
Williams %R
Neutral
Level
-57.0588
50-day SMA
Sell
Level
$0.66
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
91.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.2179)
Sell
CA Score
(Annual)
Level (-11.6211)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (12.5626)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
Stock Forecast FAQ
In the current month, CYTH has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CYTH average analyst price target in the past 3 months is $3.20.
-
Where Will Cyclo Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cyclo Therapeutics share price will rise to $3.20 per share over the next 12 months.
-
What Do Analysts Say About Cyclo Therapeutics?
Analysts are divided on their view about Cyclo Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cyclo Therapeutics is a Sell and believe this share price will drop from its current level to $2.60.
-
What Is Cyclo Therapeutics's Price Target?
The price target for Cyclo Therapeutics over the next 1-year time period is forecast to be $3.20 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CYTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cyclo Therapeutics is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of CYTH?
You can purchase shares of Cyclo Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cyclo Therapeutics shares.
-
What Is The Cyclo Therapeutics Share Price Today?
Cyclo Therapeutics was last trading at $0.63 per share. This represents the most recent stock quote for Cyclo Therapeutics. Yesterday, Cyclo Therapeutics closed at $0.62 per share.
-
How To Buy Cyclo Therapeutics Stock Online?
In order to purchase Cyclo Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is ARK Next Generation Internet ETF a Good Investment?
The ARK Next Generation Internet ETF looks like a pretty…
Why Is Marvell Stock Up?
Semiconductor and data infrastructure company Marvell Technology (NASDAQ:MRVL) absolutely trounced…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
